Product Overview – Parallax Option

Breakthrough Therapies for Antibiotic Resistant Infections

Aridis Pipeline

 

Our product candidates are highly differentiated from all antibiotics in mechanism of action, durability of action, drug resistance and safety profile. Our product pipeline targets infectious diseases that have a significant impact on life expectancy and address acute medical needs including:

 

Aridis Pipeline

AR-301 AR-105 AR-101 AR-501 AR-201 AR-401

Fully human monoclonal antibodies (mAb) against infectious disease targets are a growing area of interest as a therapeutic modality due to their strong safety profile in humans, remarkably long plasma half-life and low risk of drug resistance. Aridis has developed a suite of human mAbs as anti-infective drugs targeting key human pathogens, including S. aureus (MRSA & MSSA), P. aeruginosa, A. baumannii bacteria and respiratory syncytial virus. Complementing these mAbs is a broad spectrum anti-infective candidate based on the unique properties of gallium (PanaecinTM).